‹ ›
MYP_140711
← PREVIOUS NEXT → BACK
Basic Information
HR2-anti-P
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
36 amino acids
C172H292N48O61
Standard
Sequence
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
Physicochemical Analysis
4008.44 Da
4.20
-4.23
-4.44
-0.1174
-0.18
0.70
-0.00
42.58
138.06
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1819.18
-19.24
59.0
57.0
143.0
281.0
0.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0000219 VERIFIED: NO
Provenance & Taxonomy
Severe acute respiratory syndrome coronavirus 2 [Virus]
HR2-derived fusion inhibitor
2697049
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus 2
PaperIn silico design of antiviral peptides targeting the spike protein of SARS-CoV-2 PMID32380200 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32380200/
RECORD: Rec_0000852 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | protein-mediated cell; -cell
0.0006±0.00003 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0017376 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-CoV-WIV1 Fusion inhibition
CoV-WIV1 | 293T/ACE2 cells
2.73 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperA pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. | Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. | Sci Adv. 2019 Apr 10;5(4):eaav4580. | DOI:10.1126/sciadv.aav4580 | PMID:30989115 PMID30989115 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30989115/
RECORD: Rec_0022136 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome coronavirus 2 [Virus]
Synthetic antiviral peptide
2697049
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Middle East respiratory syndrome-related coronavirus
1 μM
IC90
PaperInhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 spike glycoprotein HRC domain PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0024356 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-HCoV-229E Fusion inhibition
HCoV-229E | Huh-7 cells
0.5357±0.0446 μM
IC50
Mammalian: 1.1 h; Yeast: 3 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
1 2 3 ... 15 NEXT LAST
Showing 5 records on this page · Page 1 of 15